Molecular basis of gynecological oncology - TopBP1 protein and its participation in the transcription process;Molekularne podstawy ginekologii onkologicznej - bialko TopBP1 i jego udzial w procesie transkrypcji

Ginekologia Polska

Volumn 83, Issue 5, 2012, Pages 363-367

  Forma, Ewa ^a   Wójcik Krowiranda, Katarzyna ^b   Bienkiewicz, Andrzej ^b   Brys, Magdalena ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Breast cancer; E2F1; HPV16 E2; Miz 1; Ovarian cancer; p53; TopBP1; Transcription regulation

Indexed keywords

CARRIER PROTEIN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TOPBP1 PROTEIN, HUMAN;

BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MUTATION; NUCLEOTIDE SEQUENCE; OVARY TUMOR; REVIEW; RISK FACTOR;

BREAST NEOPLASMS; CARRIER PROTEINS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 84864503594     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Joosse S, Brandwijk K, Mulder L, [et al.]. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer. 2011, 50, 71-81.
2. Karppinen S, Erkko H, Reini K, [et al.]. Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer. Eur J Cancer. 2006, 42, 2647-2652.
3. Supernat A, Welnicka-Jaskiewicz M, Zaczek A. Farmakogenetyka w hormonoterapii raka piersi. Wspólcz Onkol. 2010, 14, 242-247.
4. Wu J, Lu L, Yu X. The role of BRCA1 in DNA damage response. Protein Cell. 2010, 1, 117-123.
5. Synowiec A, Wcislo G, Bondar L. [et al.]. Status genu BRCA1 a zachorowania na dziedziczna postac raka jajnika. Wspólcz Onkol. 2010, 14, 72-78.
6. Lynch H, Fusaro R, Lynch J. Hereditary cancer in adults. Cancer Detect Prev. 1995, 19, 219-233.
7. Ellsworth R, Decewicz D, Shriver C, Ellsworth D. Breast cancer in the personal genomics era. Curr Genomics. 2010, 11, 146-161.
8. Ferla R, Calò V, Cascio S, [et al.]. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol. 2007, 18 Supl., 6, 93-98.
9. Hall J, Lee M, Newman B, [et al.]. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990, 250,1684-1689.
10. Miki Y, Swensen J, Shattuck-Eidens D, [et al.]. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266, 66-71.
11. Wooster R, Neuhausen S, Mangion J, [et al.]. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994, 265, 2088-2090.
12. Wooster R, Bignell G, Lancaster J, [et al.]. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378,789-792.
13. Campeau P, Foulkes W, Tischkowitz M. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet. 2008, 124, 31-42.
14. Oldenburg R, Meijers-Heijboer H, Cornelisse C, Deville P. Genetic susceptibility for breast cancer: how many more genes to be found? Crit Rev Oncol Hematol. 2007, 63,125-149.
15. Shuen A, Foulkes W. Inherited mutations in breast cancer genes risk and response. J Mammary Gland Biol Neoplasia. 2011, 16, 3-15.
16. Teng L, Zheng Y, Wang H. BRCA1/2 associated hereditary breast cancer. J Zhejiang Univ Sci B. 2008, 9,85-89.
17. Antoniou A, Easton D. Models of genetic susceptibility to breast cancer. Oncogene. 2006, 25, 5898-5905.
18. Mavaddat N, Antoniou A, Easton D, Garcia-Closas M.. Genetic susceptibility to breast cancer. Mol Oncol. 2010, 4, 174-191.
19. Beggs A, Hodgson S. Genomics and breast cancer: the different levels of inherited susceptibility. Eur J Hum Genet. 2009, 17, 855-856.
20. Mäkiniemi M, Hillukkala T, Tuusa J, [et al.]. BRCT domain-containing protein TopBP1 functions in DNA replication and damage response. J Biol Chem. 2001, 276, 30399-30406.
21. Yamane K, Kawabata M, Tsuruo T. A DNA-topoisomerase-II-binding protein with eight repeating regions similar to DNA-repair enzymes and to a cell-cycle regulator. Eur J Biochem. 1997, 250, 794-799.
22. Xu YJ, Leffak M. ATRIP from TopBP1 to ATR-in vitro activation of a DNA damage checkpoint. Proc Natl Acad Sci USA. 2010, 107, 13561-13562.
23. Yan S, Michael W. TopBP1 and DNA polymerase-alpha directly recruit the 9-1-1 complex to stalled DNA replication forks. J Cell Biol. 2009, 184, 793-804.
24. Yan S, Michael W. TopBP1 and DNA polymerase a-mediated recruitment of the 9-1-1 complex to stalled replication forks: implications for a replication restart-based mechanism for ATR checkpoint activation. Cell Cycle. 2009, 8, 2877-2884.
25. Glover J. Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain. Fam Cancer. 2006, 5, 89-93.
26. Leung C, Kellogg E, Kuhnert A, [et al.]. Insights from the crystal structure of the sixth BRCT domain of topoisomerase II beta binding protein 1. Protein Sci. 2010, 19, 162-167.
27. Wright R, Dornan E, Donaldson M, Morgan J. TopBP1 contains a transcriptional activation domain suppressed by two adjacent BRCT domains. Biochem J. 2006, 400, 573-582.
28. Yamane K, Tsuruo T. Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA. Oncogene. 1999, 18, 5194-5203.
29. Rodriguez M, Yu X, Chen J, Songyang Z. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains. J Biol Chem. 2003, 278, 52914-52918.
30. Zeng L, Hu Y, Li B. Identification of TopBP1 as a c-Abl-interacting protein and a repressor for c-Abl expression. J Biol Chem. 2005, 280, 29374-29380.
31. Glover J, Williams R, Lee M. Interactions between BRCT repeats and phosphoproteins: tangled up in two. Trends Biochem Sci. 2004, 29, 579-585.
32. Huo Y, Bai L, Xu M, Jiang T. Crystal structure of the N-terminal region of human Topoisomerase IIß binding protein 1. Biochem Biophys Res Commun. 2010, 401, 401-405.
33. Yamane K, Wu X, Chen J. A DNA damage-regulated BRCT-containing protein, TopBP1, is required for cell survival. Mol Cell Biol. 2002, 22, 555-566.
34. Yang S, Lin F, Lin W. MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep. 2008, 9, 907-915.
35. Boner W, Taylor E, Tsirimonaki E, [et al.]. A functional interaction between the human papillomavirus 16 transcription/replication factor E2 and the DNA damage response protein TopBP1. J Biol Chem. 2002, 277, 22297-22303.
36. Liu K, Luo Y, Lin F, [et al.]. TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev. 2004, 18, 673-686.
37. Kumagai A, Lee J, Yoo H, Dunphy W. TopBP1 activates the ATR-ATRIP complex. Cell. 2006, 124, 943-955.
38. Mordes D, Glick G, Zhao R, Cortez D. TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. Genes Dev. 2008, 22, 1478-1489.
39. Smits V, Warmerdam D, Martin Y, Freire R. Mechanisms of ATR-mediated checkpoint signalling. Front Biosci. 2010, 15, 840-853.
40. Takeishi Y, Ohashi E, Ogawa K, [et al.]. Casein kinase 2-dependent phosphorylation of human Rad9 mediates the interaction between human Rad9-Hus1-Rad1 complex and TopBP1. Genes Cells. 2010, 15, 761-771.
41. Donaldson M, Boner W, Morgan I. TopBP1 regulates human papillomavirus type 16 E2 interaction with chromatin. J Virol. 2007, 81, 4338-4342.
42. Herold S, Wanzel M, Beuger V, [et al.]. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell. 2002, 10, 509-521.
43. Herold S, Hock A, Herkert B, [et al.]. Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. EMBO J. 2008, 27, 2851-2861.
44. Liu K, Lin F, Ruppert J, Lin W. Regulation of E2F1 by BRCT domain-containing protein TopBP1. Mol Cell Biol. 2003, 23, 3287-3304.
45. Liu K, Bellam N, Lin H, [et al.]. Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer. Mol Cell Biol. 2009, 29, 2673-2693.
46. Chen H, Tsai S, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009, 9, 785-797.
47. Poznic M. Retinoblastoma protein: a central processing unit. J Biosci. 2009, 34, 305-312.
48. Liu S, Bekker-Jensen S, Mailand N, [et al.]. Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation. Mol Cell Biol 2006, 26:6056-6064.
49. Liu K, Paik J, Wang B, [et al.]. Regulation of TopBP1 oligomerization by Akt/PKB for cell survival. EMBO J. 2006, 25, 4795-4807.
50. Reisman D, Glaros S, Thompson E. The SWI/SNF complex and cancer. Oncogene. 2009, 28, 1653-1668.
51. Gunawardena R, Fox S, Siddiqui H, Knudsen E. SWI/SNF activity is required for the repression of deoxyribonucleotide triphosphate metabolic enzymes via the recruitment of mSin3B. J Biol Chem. 2007, 282, 20116-20123.
52. Engelmann D, Pützer B. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance. Drug Resist Updat. 2010, 13,119-131.
53. Yu F, Megyesi J, Safirstein R, Price P. Involvement of the CDK2-E2F1 pathway incisplatin cytotoxicity in vitro and in vivo. Am J Physiol Renal Physiol. 2007, 293, F52-59.
54. Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol. 2011, 2011, 603925.
55. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer. 2009, 9, 738-748.
56. Qian Y, Chen X. Tumor suppression by p53: making cells senescent. Histol Histopathol. 2010, 25, 515-526.
57. Melino G, Lu X, Gasco M, [et al.]. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci. 2003, 28, 663-670.
58. Wanzel M, Herold S, Eilers M. Transcriptional repression by Myc. Trends Cell Biol. 2003, 13, 146-150.
59. Wollmann Y, Schmidt U, Wieland G, [et al.]. The DNA topoisomerase II beta binding protein 1 (TopBP1) interacts with poly (ADP-ribose) polymerase (PARP-1). J Cell Biochem. 2007, 102, 171-182.
60. Honda Y, Tojo M, Matsuzaki K, [et al.]. Cooperation of HECT-domain ubiquitin ligase hHYD and DNA topoisomerase II-binding protein for DNA damage response. J Biol Chem. 2002, 277, 3599-3605.
61. Scheffner M, Staub O. HECT E3s and human disease. BMC Biochem. 2007, 8 Supl. 1, 6.
62. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci. 2006, 110, 525-541.
63. Kedzia W, Pruski D, Józefak Agata, [i wsp.]. Genotypowanie onkogennych wirusów brodawczaka ludzkiego u kobiet z rozpoznaniem HG SIL. Ginekol Pol. 2010, 81, 740-744.
64. Faridi R, Zahra A, Khan K, Idcees L. Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol J. 2011, 8, 269.